Iraida Loinaz, coordinator of the PneunoNP project, attends the EuroNanoForum 2017 conference.
EuroNanoForum 2017 is an international event that focus on how nano and materials technologies can strengthen competitiveness across all European industries. The event takes place in Malta from 21th and 23th June 2017.
Nanotechnology is expected to gain importance in the near future in many industries. For example, nanomedicine could solve numerous healthcare challenges especially in the field of drug-delivery. However, from the pharmaceutical point of view, there is insufficient clinical data that allows the assessment of the role of nanotechnology in the potential of these products.
It is time to push those promising developments to the clinical stage. Iraida Loinaz’s talk will show real examples on how is possible to translate a lab scale protocol, into a robust GMP manufacturing process, and those key aspects to take into account to reduce the time of development.
Iraida Loinaz, coordinator of PneunoNP project, is the Health business development Manager of IK4-Cidetec. In the last years Dr. Loinaz’s group has been specialized in translational research. They are establishing a pilot plant operating under GMP for the production of nanopharmaceuticals.
“It is my first time attending EuroNanoForum,” Dr Loinaz said. “I really look forward to meeting main stakeholders in the field of nanotechnologies for health and share our experiences in the field.”
Find all the necessary information related to the event on: www.eccmid.org.
The raise of antimicrobial resistance urges the development of novel approaches to bring antibiotics into bacteria. This workshop provides an interdisciplinary overview of EU funded research in this field. It is organized by PneumoNP with ITN/IMI-Translocation, FORMAMP and NAREB projects. The whole PneumoNP team is present at the event.
Topics: From understanding the crossing of membrane barrier to the development of new nanotechnology-based drugs
The workshop will cover diverse aspects of the development of novel drugs: How new molecules works on resistant bacteria; New methods of delivery (nanoencapsulation); Labeling of molecules and imaging analysis; Different models used to test efficiency of the drugs; and Process of translation to clinical development.
Especially, do not miss the presentations of PneumoNP researchers:
– “News from the EU project PneumoNP”, by Iraida Loinaz (IK4-CIDETEK, Spain) on 10th July at 18:00
– “Polymeric nanoparticles for treating bacterial infections”, by Marco Marradi (IK4-CIDETEC, Spain) on 11th July at 10:55
– “Determination of regional distribution in the lungs using nuclear imaging”, by Jordi Llop (CIC biomaGUNE, Spain) on Tuesday 12th at 11:10
– “Rat models of K. pneumoniae-ESBL and K. pneumoniae-KPC pneumonia, set-up and clinical validation” by Hessel van der Weide (Erasmus Medical Centre, The Netherlands) on Tuesday 12th at 11:30
– “Preclinical efficacy and safety testing of antimicrobial compounds” by Sabine Wronski (ITEM, Germany) on Tuesday 12th at 11:50
– “Clinical development of antimicrobial peptides -opportunities and challenges from a SME perspective”, Magnus Strandh (Adenium Biotech, Denmark) on Tuesday 12th at 12:10